The company's low ROE and high debt usage is worrisome. Investors should ponder on the company's performance if borrowing becomes difficult due to changing credit markets. A high ROE without debt indicates a high quality business.
Portland General Electric's recent ROCE trends hint potential multi-bagger isn't strong. Despite growth pursuits, falling returns suggest short term brightness may be lacking. Further investigation into the stock is advised.
Insiders' recent selling activities signal shares aren't cheap. No insider purchases in last 3 months or year ignite caution before buying stock. Some alignment exists between management and smaller shareholders.
Gainers: •$Okta (OKTA.US)$+15.8% (In reaction to earnings) •$StoneCo (STNE.US)$+12.9% (In reaction to earnings) •$Turning Point Therapeutics (TPTX.US)$+116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025) •$Amylyx Pharmaceuticals (AMLX.US)$+24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
Portland General Electric Stock Forum
• $Fortinet (FTNT.US)$ : BMO Capital Upgrades to Outperform from Market Perform - PT $350 (from $325)
• $Microchip Technology (MCHP.US)$ : Stifel Upgrades to Buy from Hold - PT $75 (from $70)
• $Ovintiv (OVV.US)$ : JPMorgan Upgrades to Overweight from Neutral - PT $64 (from $56)
• $Riot Platforms (RIOT.US)$ : Compass Point Upgrades to Buy from Neutral - PT $14 (from $30)
• $Snowflake (SNOW.US)$ : Jefferies Upgrades to Buy f...
• $Okta (OKTA.US)$ +15.8% (In reaction to earnings)
• $StoneCo (STNE.US)$ +12.9% (In reaction to earnings)
• $Turning Point Therapeutics (TPTX.US)$ +116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025)
• $Amylyx Pharmaceuticals (AMLX.US)$ +24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
• $Ciena (CIEN.US)$: B.Riley Upgrades to Buy from Neutral - PT $67 (from $65)
• $Ecolab (ECL.US)$: Credit Suisse Upgrades to Outperform from Neutral - PT $195 (from $180)
• $Hersha Hospitality Trust (HT.US)$: Jefferies Upgrades to Buy from Neutral - PT $13 (from $11)
• $Martin Marietta Materials (MLM.US)$: JPMorgan Upgrades to Overweight from Neutral - PT $410 (from $420)
• $Portland General Electric (POR.US)$: Goldman Sachs Upgrades to Buy from Neutral - P...
• $Baker Hughes (BKR.US)$ : HSBC Upgrades to Buy from Hold - PT $38.30
• $United Breweries Co Inc (CCU.US)$ : HSBC Upgrades to Buy from Hold - PT $17
• $Capital City Bank Group (CCBG.US)$ : Piper Sandler Upgrades to Overweight from Neutral - PT $31.50 (from $29)
• $Hub Group (HUBG.US)$ : Susquehanna Upgrades to Positive from Neutral - PT $83 (from $92)
• $Interactive Brokers (IBKR.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $90
• $JB Hunt Transport Services (JBHT.US)$ : Susqueh...
• $TechnipFMC (FTI.US)$ : Societe Generale Upgrades to uy from Hold - PT $10
• $Lululemon Athletica (LULU.US)$ : Truist Securities Upgrades to Buy from Hold - PT $495 (from $390)
• $NorthWestern (NWE.US)$ : Barclays Upgrades to Equal Weight From Underweight - PT $62 (from $57)
• $Portland General Electric (POR.US)$ : Barclays Upgrades to EqualWeight From Underweight - PT $57 (from $53)
• $Pricesmart (PSMT.US)$ : Scotiabank Upgrades to Sector Outperform Fro...
• $CDW Corp (CDW.US)$: Stifel Upgrades to Buy from Hold - PT $210 (from $200)
• $Corteva (CTVA.US)$ : Loop Capital Upgrades to Buy from Hold - PT $69
• $CoreCivic, Inc. (CXW.US)$ : Wedbush Upgrades to Outperform from Neutral - PT $17 (from $10.85)
• $Delta Air Lines (DAL.US)$ : Barclays Upgrades to Overweight from Equalweight - PT $60 (from $42)
• $H.B. Fuller (FUL.US)$ : Baird Upgrades to Outperform from Neutral - PT $85
• $Huntington Ingalls Industries (HII.US)$ : Cowen U...
No comment yet